#None #cystic fibrosis #Epicore Biosystems #MECFA

Collaboration to Improve Cystic Fibrosis Testing

In a groundbreaking initiative, Epicore Biosystems has announced a collaboration with the Middle East Cystic Fibrosis Association (MECFA) to enhance the accessibility of vital sweat chloride testing for cystic fibrosis (CF) patients. This innovative approach integrates state-of-the-art wearable technology developed by Epicore with MECFA's efforts to expand care for CF across the Middle East, North Africa, and Central Asia.

Cystic fibrosis is a genetic condition that affects the lungs and digestive system. Identifying the disease early through accurate testing is crucial for improving health outcomes. Traditionally, sweat chloride testing is performed in clinical settings and requires specialized equipment and trained personnel. This system has remained largely unchanged for decades, posing significant barriers to timely diagnosis, particularly in underserved regions. Christine Noke, President and CEO of MECFA, emphasized the importance of fast, reliable testing that does not necessitate clinic visits, stating, "Every family navigating this disease deserves access to testing that is fast, accurate, and doesn’t require a specialized clinic visit."

Streamlining Sweat Testing with Wearable Technology

Epicore’s solution, the Chloride Tracker, is a wearable device that transforms the conventional sweat testing process into a convenient, real-time monitoring tool. By combining sweat induction and chloride sensing capabilities into a single device, the Chloride Tracker enables on-the-spot analysis, drastically reducing the need for laboratory processing time. Clinically validated in CF studies published in recognized journals like Nature Digital Medicine, this device is not only promising for patients in high-income countries but also particularly advantageous in regions with limited medical resources.

Dr. Roozbeh Ghaffari, CEO and Co-Founder of Epicore, has expressed the urgency of evolving CF monitoring technologies to match medical advancements. He acknowledged that while the diagnostic methods for CF have been effective, they remain antiquated, stating, "By integrating stimulation and sensing into a single wearable device, we can make sweat testing and chloride monitoring simpler and more accessible."

Addressing Healthcare Disparities in the Middle East

The collaboration seeks to bridge significant healthcare gaps in the Middle East, where newborn screening for CF is not widely practiced, with Türkiye being the only nation with a nationwide screening program. Consequently, many children do not receive a diagnosis until the disease has already caused irreversible damage. Prof. Dr. Bülent Karadağ, Director of the Marmara University Cystic Fibrosis Center, highlighted the pressing necessity for reliable testing solutions in the region, advocating that early, accessible testing could drastically change lives.

The upcoming clinical trials aimed at evaluating the Chloride Tracker will take place in Istanbul at Marmara University, which boasts Europe's largest CF center. These trials are intended to assess the technology's efficiency and pave the way for greater adoption throughout MECFA's member countries.

The Future of Cystic Fibrosis Care

Both Epicore and MECFA are aware that effective CF management extends beyond just diagnostics; it also encompasses ongoing patient monitoring and support. Current CFTR modulator therapies underscore the critical importance of sweat chloride levels as a biomarker for treatment effectiveness. By improving access to testing, this collaboration hopes to not only enhance diagnosis but ultimately improve patient care across various demographics.

The combined efforts of these two organizations aim to set a standard for innovation in CF testing, ensuring families, regardless of their location, have access to the tools necessary for managing this complex condition effectively. Dr. Susanna McColley from the Lurie Children’s Hospital highlighted the importance of early diagnosis, advocating for this initiative: "Lack of access to sweat testing in the Middle East is a pervasive problem that requires a solution that is widely available and affordable."

Ultimately, the partnership between Epicore Biosystems and MECFA is a vital step towards making reliable cystic fibrosis testing universally accessible, thereby improving health outcomes for countless children facing this hereditary disease.